<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03990727</url>
  </required_header>
  <id_info>
    <org_study_id>RETMxMap</org_study_id>
    <nct_id>NCT03990727</nct_id>
  </id_info>
  <brief_title>Phenotype Correlates Genotype of Inherited Retina Dystrophies, Retinitis Pigmentosa, Con&gt;Rod Dystrophies.</brief_title>
  <official_title>Phenotype Correlates Genotype of Inherited Retina Dystrophies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MejoraVisionMD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Maisonneuve-Rosemont Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Retina and Genomics Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>MejoraVisionMD</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with retina dystrophies (retinitis pigmentosa, cone&gt;rods dystrophies, Usher and
      syndromic) will be correlated with genotype and validate inheritance mode by segregation
      analysis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with retina dystrophies (retinitis pigmentosa, cone&gt;rods dystrophies, Usher and
      syndromic, etc.) will be correlated with genotype and validate inheritance mode by
      segregation analysis. Ocular exam of proband, parents and two unaffected siblings is needed,
      retina analysis, autofluorescence and ocular coherence tomography (OCT) are needed as well as
      family map. Blood samples 10ml max blood extraction will be sent and genotype will be
      analyzed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2009</start_date>
  <completion_date type="Anticipated">September 30, 2025</completion_date>
  <primary_completion_date type="Actual">June 13, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Family-Based</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Gene-molecular variation to correlate with phenotype based on autofluorescence, retina analysis,</measure>
    <time_frame>8 years</time_frame>
    <description>Molecular variation correlates with specific phenotype based on autofluorescence, retina analysis, macular coherence tomography.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Preliminary Natural History</measure>
    <time_frame>5 years</time_frame>
    <description>Ocular exam, retina analysis, autofluorescence and OCTs will be described in time frame</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">17000</enrollment>
  <condition>Retinitis Pigmentosa</condition>
  <condition>Cone Dystrophy</condition>
  <condition>Usher Syndromes</condition>
  <condition>Retina; Dystrophy</condition>
  <arm_group>
    <arm_group_label>Retinitis pigmentosa</arm_group_label>
    <description>Any type of retina dystrophy with pigment / retinitis pigmentosa</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usher Syndrome</arm_group_label>
    <description>Retina dystrophy or retinitis pigmentosa associated with audition problems</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cone&gt;rod syndromes</arm_group_label>
    <description>Retina dystrophy diagnosed or started in central vision.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Retinitis pigmentosa sx</arm_group_label>
    <description>Retinitis pigmentosa with any type of other features</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Retina Analysis-mosaic</intervention_name>
    <description>Fundus retina pattern study</description>
    <arm_group_label>Cone&gt;rod syndromes</arm_group_label>
    <arm_group_label>Retinitis pigmentosa</arm_group_label>
    <arm_group_label>Retinitis pigmentosa sx</arm_group_label>
    <arm_group_label>Usher Syndrome</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Autofluorescence</intervention_name>
    <description>Fundus reflectance-functionality</description>
    <arm_group_label>Cone&gt;rod syndromes</arm_group_label>
    <arm_group_label>Retinitis pigmentosa</arm_group_label>
    <arm_group_label>Retinitis pigmentosa sx</arm_group_label>
    <arm_group_label>Usher Syndrome</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>OCT- 1 micra</intervention_name>
    <description>Fine tomography fundus retina</description>
    <arm_group_label>Cone&gt;rod syndromes</arm_group_label>
    <arm_group_label>Retinitis pigmentosa</arm_group_label>
    <arm_group_label>Retinitis pigmentosa sx</arm_group_label>
    <arm_group_label>Usher Syndrome</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Genotype analysis</intervention_name>
    <description>Molecular target retina dystrophy analysis</description>
    <arm_group_label>Cone&gt;rod syndromes</arm_group_label>
    <arm_group_label>Retinitis pigmentosa</arm_group_label>
    <arm_group_label>Retinitis pigmentosa sx</arm_group_label>
    <arm_group_label>Usher Syndrome</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Inherited retina dystrophies / Retinitis pigmentosa, LCA, Cone-rod dystrophy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of inherited retina dystrophy or retinitis pigmentosa

          2. Must be able to perform all study tests.

          3. Must be able to visit every year.

        Exclusion Criteria:

        1) Not willing to visit every year.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>A Villanueva, MD</last_name>
    <phone>019992233623</phone>
    <email>dr.villanueva@mejoravisionmd.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gelly Cuevas, MS</last_name>
    <phone>+521 (999) 4060506</phone>
    <email>research.biobanks@mejoravisionmd.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Retina and Genomics Institute</name>
      <address>
        <city>Merida</city>
        <state>Yucatan</state>
        <zip>97130</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>AL Villanueva, MD</last_name>
      <phone>9992233623</phone>
      <email>dr.villanueva@mejoravisionmd.com</email>
    </contact>
    <contact_backup>
      <last_name>Gelly Cuevas, MS</last_name>
      <phone>01 (999) 4060586</phone>
      <email>alva@mejoravisionmd.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <results_reference>
    <citation>Villanueva, Adda L., et al.</citation>
  </results_reference>
  <results_reference>
    <citation>Villanueva, A. L., Langlois, M., Mongrain, I., Provost, S., Asselin, G., Dub√©, M. P., ... &amp; Ayyagari, R. (2015). ARRP microarray and Exome analysis revealed known and novel mutations in Mexican pedigrees. Investigative Ophthalmology &amp; Visual Science, 56(7), 2866-2866.</citation>
  </results_reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 11, 2019</study_first_submitted>
  <study_first_submitted_qc>June 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2019</study_first_posted>
  <last_update_submitted>June 16, 2019</last_update_submitted>
  <last_update_submitted_qc>June 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Usher Syndromes</mesh_term>
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
    <mesh_term>Cone Dystrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>It will be share by publication papers.</ipd_description>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>1a</ipd_time_frame>
    <ipd_access_criteria>To organism with known knowledge in the field. To expand analysis in same field. Via digital, by contacting administrator.</ipd_access_criteria>
    <ipd_url>http://mejoravisionmd.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

